Patent Assignment
Reel/Frame 029057/0342
Release of Security Interest
Recorded: 2012-10-01
Pages: 10
Assignor
ELI LILLY AND COMPANY
Executed: 2012-08-08
Assignee
AMYLIN PHARMACEUTICALS, INC.
9360 TOWNE CENTER DRIVE, SAN DIEGO, CALIFORNIA, 92121
Covered Properties
(55)
Methods for Regulating Gastrointestinal Motility
Patent:
6,858,576 →
Application:
08/908,867 →
Use of Exendins and Agonists Thereof for the Reduction of Food Intake
Polynucleotides Encoding Proexendin, and Methods and Uses Thereof
Patent:
6,723,530 →
Application:
09/019,172 →
Metabolic Intervention with Glp-1 to Improve the Function of Ischemic and Reperfused Tissue
Patent:
6,284,725 →
Application:
09/302,596 →
Use of Exendins and Agonists Thereof for the Treatment of Gestational Diabetes Mellitus
Patent:
6,506,724 →
Application:
09/323,867 →
Inotropic and Diuretic Effects of Exendin and Glp-1
Patent:
6,703,359 →
Application:
09/622,105 →
Exendin Improves Beta-Cell Response in Subjects with Impaired Glucose Tolerance
Patent:
7,265,087 →
Application:
09/719,410 →
Metabolic Intervention with Glp-1 to Improve the Function of Ischemic and Reperfused Tissue
Novel Exendin Agonist Formulations and Methods of Administration Thereof
Patent:
6,902,744 →
Application:
09/889,330 →
Methods for Glucagon Suppression
Patent:
6,872,700 →
Application:
09/889,331 →
Methods of Treating Obesity Using Pyy[3-36]
Compositions and Methods for Treating Peripheral Vascular Disease
Exendins, Exendin Agonists, and Methods for Their Use
Methods and Compositions for Treating Polycystic Ovary Syndrome
Treatment of Acute Coronary Syndrome with Exendin-4
Novel Methods and Compositions for Enhanced Transmucosal Delivery of Peptides and Proteins
Methods and Compositions for Treating Polycystic Ovary Syndrome
Treatment of Cardiac Arrhythmias with Glp-1 Receptor Ligands
Method for Enhanced Parenteral Nutrition
Pharmaceutical Compositions Containing Exendins
Exendins and Exendin Agonists for Weight Reduction and Obesity
Exendin Pharmaceutical Compositions
Metabolic Intervention with Glp-1 or Its Biologically Active Analogues to Improve the Function of the Ischemic and Reperfused Brain
Patent:
41,288 →
Application:
10/913,309 →
Use of Exendins and Agonists Thereof for Lowering Plasma Lipid
Compositions and Methods for Treating Peripheral Vascular Disease
Methods and Compositions for Treating Polycystic Ovary Syndrome
Polymer-Based Sustained Release Device
Poly(Lactide-Co-Glycolide) Based Sustained Release Microcapsules Comprising a Polypeptide and a Sugar
Transmucosal delivery of peptides and proteins
Application:
11/628,123 →
Publication:
US 2009/0069226
Use of Glp-1 and Agonists Thereof to Prevent Cardiac Myocyte Apoptosis
Application:
11/857,951 →
Publication:
US 2009/0264352
Use of Exendins and Agonists Thereof for the Treatment of Gestational Diabetes Mellitus
Application:
11/869,013 →
Publication:
US 2008/0125353
Methods of Controlling Binge Eating Disorders
Pharmaceutical Formulations Comprising Incretin mimetic Peptide and Aprotic Polar Solvent
Application:
11/910,723 →
Publication:
US 2008/0200383
Use of Exendin and Analogs Thereof To Delay or Prevent Cardiac Remodeling
Exendin-4 to Treat Nonalcoholic Steatohepatitis and Nonalcoholic Fatty Liver Disease
Methods of Treatment Using Exendin Peptides or Glp-1 Peptides
Endothelin and Endothelin Receptor Agonists in the Treatment of Metabolic Diseases
Application:
12/294,235 →
Publication:
US 2010/0004166
Exendins and Exendin Agonist Analogs to Regulate Gastrointestinal Motility
DPP-IV Resistant GIP Hybrid Polypeptides with Selectable Properties
Lyophilized Formulations of Exendins and Exendin Agonist Analogs
Polymer-Based Sustained Release Device
Application:
12/483,871 →
Publication:
US 2009/0247463
Pancreatic Polypeptide Family Motifs, Polypeptides and Methods Comprising the Same
Treatment of Cardiac Arrhythmias
Exendin and Exendin Agonists for Eating Disorders
Treatment of Hibernating Myocardium with an Exendin Peptide
Glp-1 Receptor Agonist Bioassays
Exendins to Lower Cholesterol and Triglycerides
Application:
12/992,060 →
Publication:
US 2011/0263496
Methods for Lowering Plasma Glucagon with Exendins and Exendin Agonist Analogs
Application:
13/045,334 →
Publication:
US 2011/0281798
Sustained Release Formulations Using Non-Aqueous Carriers
Methods of Treatment Using Exendin Peptides or Glp-1 Peptides
Methods for Treating Diabetes and Reducing Body Weight
Methods of using GLP-1 receptor agonists to treat pancreatitis
Exendins and Exendin Agonist Analogs to Regulate Gastrointestinal Motility
Application:
13/226,975 →
Publication:
US 2012/0004168
GLP-1 Receptor Agonists for Islet Cell Transplantation
Application:
61/426,076 →
Methods for Treating Diabetes with Extended Release Formulations of Glp-1 Receptor Agonists
Application:
61/501,018 →
Related Assignments
(7)
Other recorded transfers of the patents in this record — the chain of ownership.
Release of Security Interest
Oct 1, 2012
From: ELI LILLY AND COMPANY
To: AMYLIN PHARMACEUTICALS, INC.
Reel/Frame 029057/0626 →
Change of Name
Oct 12, 2012
From: AMYLIN PHARMACEUTICALS, INC.
To: AMYLIN PHARMACEUTICALS, LLC
Reel/Frame 029123/0769 →
Change of Name
Oct 25, 2012
From: AMYLIN PHARMACEUTICALS, INC.
To: AMYLIN PHARMACEUTICALS, LLC
Reel/Frame 029198/0295 →
Change of Name
Oct 25, 2012
From: AMYLIN PHARMACEUTICALS, INC.
To: AMYLIN PHARMACEUTICALS, LLC
Reel/Frame 029198/0345 →
Change of Name
Oct 25, 2012
From: AMYLIN PHARMACEUTICALS, INC.
To: AMYLIN PHARMACEUTICALS, LLC
Reel/Frame 029198/0319 →
Change of Name
Oct 25, 2012
From: AMYLIN PHARMACEUTICALS, INC.
To: AMYLIN PHARMACEUTICALS, LLC
Reel/Frame 029198/0340 →
Amylin Pharmaceuticals, Llc Assigns an Equal and Undivided One-Half of Its Entire Right, Title and Interest to Astrazeneca Pharmaceuticals Lp
Oct 26, 2012
From: AMYLIN PHARMACEUTICALS, LLC
To: ASTRAZENECA PHARMACEUTICALS LP
Reel/Frame 029195/0555 →